Company: INKT
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001193125-25-159014
Chunk: 22

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 22
---
 may not achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place significant reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Important factors that could cause actual results and events to differ materially from those indicated in the forward-looking statements include the following:

| • |     | the initiation, timing, process and results of our research and development programs, preclinical studies and 
 clinical trials;                                                                                              |

| • |     | our ability to demonstrate, and the timing of, preclinical proof-of-concept in vivo for multiple programs; |

| • |     | our ability to advance any product candidates that we may develop and successfully complete clinical trials and 
 obtain licensure;                                                                                               |

| • |     | our ability to quickly leverage our initial programs and to progress additional programs to create a clinical 
 portfolio;                                                                                                    |

| • |     | the implementation of our strategic plans for our business, programs, product candidates and technology; |

| • |     | the scope of protection we are able to establish and maintain for intellectual property rights covering our 
 product candidates and technology;                                                                          |

| • |     | developments related to our competitors and our industry; |

| • |     | our ability to maintain our collaborative relationship with Agenus Inc., as well as our ability to identify and 
 enter into future license agreements and collaborations;                                                        |

| • |     | regulatory developments in the United States and foreign countries; |

| • |     | our ability to attract and retain key scientific and management personnel; and |

| • |     | our use of proceeds from this offering, estimates of our expenses, capital requirements and needs for additional 
 financing.                                                                                                       |

The forward-looking statements included in this prospectus are made only as of the date hereof. You should not rely upon forward-looking statements as predictions of future events. We cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by applicable law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes in our expectations. 5

You should read this prospectus, any prospectus supplement and the documents that we incorporate by
reference herein and therein completely and with the understanding that our actual future results, levels of activity, performance and events and